KEROS THERAPEUTICS INC (KROS)
US4923271013 - Common Stock
ChartMill assigns a Buy % Consensus number of 88% to KROS. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 90.65. This target is 61.19% above the current price.
KROS was analyzed by 16 analysts. The buy percentage consensus is at 88. So analysts seem to be very confident about KROS.
In the previous month the buy percentage consensus was at a similar level.
KROS was analyzed by 16 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-03-27 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-03-13 | Truist Securities | Reiterate | Buy -> Buy |
| 2024-03-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-12-08 | Wells Fargo | Initiate | Overweight |
| 2023-11-13 | Wedbush | Reiterate | Outperform -> Outperform |
| 2023-08-31 | Wedbush | Reiterate | Outperform -> Outperform |
| 2023-08-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-08 | Wedbush | Reiterate | Outperform -> Outperform |
| 2023-08-07 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-07-31 | Wedbush | Initiate | Outperform |
| 2023-07-26 | B of A Securities | Initiate | Buy |
| 2023-06-09 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-05-08 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-05-05 | Piper Sandler | Maintains | Overweight |
| 2023-03-06 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-02-14 | Cowen & Co. | Initiate | Outperform |
| 2022-12-13 | BTIG | Maintains | Buy |
| 2022-10-18 | Truist Securities | Initiate | Buy |
| 2022-07-26 | BTIG | Initiate | Buy |